廣告

AbbVie clinches Shire deal

AbbVie succeeds in its pursuit of Shire with a $53 billion deal which will give the U.S. pharma giant access to Shire's premium medicines for rare diseases, and, potentially, slash its tax bills. David Pollard reports.